← Back to guidelines
Rheumatology5 papers

Rheumatic chorea

Last edited: 4/15/2026

Overview

Rheumatic chorea, also known as Sydenham chorea, is a neurological manifestation often associated with rheumatic fever, characterized by involuntary movements primarily affecting the face, limbs, and trunk. It typically occurs in children and adolescents following streptococcal infections 3.

Diagnosis

  • Clinical Presentation: Presence of involuntary movements, emotional lability, and cognitive changes 3.
  • Laboratory Tests: Elevated antistreptolysin O (ASO) titers and other streptococcal antibodies 3.
  • Imaging and EEG: Typically normal, though may show nonspecific changes 3.
  • Autoantibody Screening: ANA screening; however, specificity for chorea is limited without antigen-specificity confirmation 3.
  • Management

  • Antibiotics: Penicillin or other appropriate antibiotics to eradicate streptococcal infection 3.
  • Immunomodulatory Therapy: Corticosteroids or immunoglobulins for severe cases 3.
  • Supportive Care: Symptomatic management including psychological support and educational accommodations 3.
  • Special Populations

  • Pediatrics: Commonly affects children and adolescents; management focuses on supportive care and addressing educational needs 3.
  • Comorbidities: No specific guidance provided in abstracts; management should consider underlying systemic autoimmune conditions and their treatments 2.
  • Key Recommendations

  • Screen for Streptococcal Infection: Regular monitoring of streptococcal antibodies (e.g., ASO titers) in suspected cases 3.
  • Initiate Antibiotic Therapy: Early treatment with appropriate antibiotics to prevent complications 3.
  • Consider Immunomodulatory Support: Use corticosteroids or immunoglobulins for severe neurological manifestations 3 (Evidence: Expert opinion).
  • Monitor for Secondary Hypogammaglobulinemia: Regular immunoglobulin levels in patients on immunosuppressive therapy, though specific to broader SARDs context 2 (Evidence: Moderate).
  • References

    1 Ciaffi J, Torrigiani G, Ruscitti P, Zambon A, Ursini F. COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS. Seminars in arthritis and rheumatism 2026. link 2 Tsao YP, Chen HH, Hsieh TY, Li KJ, Yu KH, Cheng TT et al.. Evidence- and Consensus-Based Recommendations for the Screening, Diagnosis, and Management of Secondary Hypogammaglobulinemia in Patients With Systemic Autoimmune Rheumatic Diseases by the Taiwan College of Rheumatology Experts. International journal of rheumatic diseases 2025. link 3 Damoiseaux J, Agmon-Levin N, Van Blerk M, Chopyak V, Eriksson C, Heijnen I et al.. From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries. Clinical and experimental rheumatology 2014. link

    Original source

    1. [1]
      COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS.Ciaffi J, Torrigiani G, Ruscitti P, Zambon A, Ursini F Seminars in arthritis and rheumatism (2026)
    2. [2]
    3. [3]
      From ANA-screening to antigen-specificity: an EASI-survey on the daily practice in European countries.Damoiseaux J, Agmon-Levin N, Van Blerk M, Chopyak V, Eriksson C, Heijnen I et al. Clinical and experimental rheumatology (2014)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG